FDA clears Bard's biliary stent:
This article was originally published in Clinica
Executive Summary
CR Bard has received US FDA 510(k) clearance for its next-generation self-expanding nitinol biliary stent for treating malignant biliary obstructions. The product uses the company's radiopaque marker technology that improves radiopacity, allowing for better stent visualisation before and after the stent has been placed. Nitinol stents are rapidly becoming the product of choice for treating malignant biliary obstructions, which affect over 30,000 people in the US every year, says the Murray Hill, New Jersey company. The stent is being marketed through Bard's Peripheral Technologies division.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.